
REFERENCES

- 1- **Abdel-Wahab MF, Zakaria S, Kamel M, et al.** High seroprevalence of hepatitis C infection among risk groups in Egypt. **Am J Trop Med Hyg (1994); 51:** 563–567.
 - 2- **Anand BS, Currie S, Dieperink E, Bini EJ, et al.** Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. **Gastroenterology 2006;** 130:1607–1616.
 - 3- **Annika Kau, Johannes Vermehren, Christoph Sarrazin.** Treatment predictors of a sustained virologic response in hepatitis B and C. **Journal of Hepatology 49 (2008) 634–651**
 - 4- **Askarieh G, Alsiö A, Pugnale P, et al.** "Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C". **Hepatology (2010) :1523–30.**
Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C et al"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials". **Hepatology (2010) : 1176–84.**
-

-
-
- 5- **Berg T, Sarrazin C, Herrmann E, et al.** Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. **Hepatology** 2003; 37:600–609.
 - 6- **Berg T, von Wagner M, Nasser S, Sarrazin C, et al.** Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. **Gastroenterology** 2006; 130:1086-1097.
 - 7- **Bonkovsky HI, and Woolley JM.** Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. **Hepatology** 1999; 29:264-270.
 - 8- **Bonkovsky HL, Naishadham D, Lambrecht RW, et al.** Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. **Gastroenterology** 2006;131:1440–1451.
 - 9- **Boyer, JL (2001).** Liver cirrhosis and its development: proceedings of the Falk Symposium.
 - 10- **Bressler BL, Guindi M, Tomlinson G, Heathcote J. et al** High body mass index is an independent risk factor
-
-

for nonresponse to antiviral treatment in chronic hepatitis C. **Hepatology** 2003;38:639–644.

- 11- **Campbell JV, Hagan H, Latka MH, et al.** "High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities". *Drug and Alcohol Dependence* (2006) : 259–65..
 - 12- **Caruntu FA, Benea L.** "Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment". *Journal of Gastrointestinal and Liver Diseases* (2006): 249–56..
 - 13- **Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, et al.** "Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment". *Clinical Infectious Diseases* (2006): 1277–83.
 - 14- **Chang KM.** Immunopathogenesis of hepatitis C virus infection. *Clin Liver Dis* 2003;7:89-105.
 - 15- **Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM.** Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. **Hepatology** 2007; 46:22–31.
-

-
-
- 16- **Chitsulo L, Engels D, Montresor A & Savioli L.** The global status of schistosomiasis and its control. **Acta Trop** 2000; 77: 41–51.
 - 17- **Choo QL, Kuo G, Weiner AJ,** "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome". **Science (1989):** 359–62.
 - 18- **Conjeevaram HS, Fried MW, Jeffers LJ, et al.** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. **Gastroenterology** 2006; 131:470–477.
 - 19- **Cox AL, Netski DM, Mosbruger T, et al.** "Prospective evaluation of community-acquired acute-phase hepatitis C virus infection". **Clinical Infectious Diseases (2005)** 951–8..
 - 20- **Daniel W. Bradley V. Chiron Corporation,** 136 F. 3d 1317 (U.S. Court of Appeals for the Federal Circuit, 1998)
 - 21- **Distante S, Bjoro K, Hellum KB, et al.** Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. **Liver** 2002; 22:269–275.
-
-

-
-
- 22- **El-Kady IM, Lotfy M, Badra G,** Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and *Schistosoma mansoni* infections. **Scand J Immunol 2005;** 61: 87-91.
- 23- **El-Khoby T, Galal N, Fenwick A, *et al.*** The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates. **Am J Trop Med Hyg 2000;** 62: 88–99.
- 24- **Elmén, Joacim *et al.*** "LNA-mediated microRNA silencing in non-human primates." (2008): 896-899.
- 25- **Enomoto, Nobuyuki; Maekawa, Shinya.** "HCV Genetic Elements Determining the Early Response to Peginterferon and Ribavirin Therapy". *Intervirology* (2010): 66..
- 26- **Everson GT, Hoefs JC, Seeff LB, *et al.*** Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. **Hepatology 2006;** 44:1675–1684.
- 27- **Everson GT.** Treatment of chronic hepatitis C in patients with decompensated cirrhosis. **Rev Gastroenterol Disord. 2004;** 4 Suppl 1:S31-8..
-
-

-
-
- 28- **Falconer K, Askarieh G, Weis N, et al.** "IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV". *Scandinavian Journal of Infectious Diseases*: (2010).
- 29- **Falconer K, Sandberg JK, Reichard O, et al.** "HCV/HIV coinfection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment". *Scandinavian Journal of Infectious Diseases* (2009) : 881–5.
- 30- **Ferenci P, Fried MW, Shiffman ML, et al.** Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. *J Hepatol* 2005; 43:425-433.
- 31- **Ferenci P, Laferl H, Scherzer TM, et al.** Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology* 2008.
- 32- **Fracanzani AL, Conte D, Fraquelli M, et al.** Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. *Hepatology* 2001;33:647–651.
-
-

-
-
- 33- **Franciscus, Alan.** "Hepatitis C Treatments in Current Development, " HCV Advocate (2010): 1-22.
- 34- **Frank C, Mohamed MK, Strickland GT, et al..** "The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt". Lancet(2000): 887–91..
- 35- **Fried MW, Hadziyannis SJ, Shiffman M, et al..** Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. **J Hepatol** 2008; 48 (Suppl.2):5A.
- 36- **Fried MW, Shiffman ML, Reddy KR, Smith et al.** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. **N Engl J Med.** Sep 26 2002; 347(13):975-82..
- 37- **Fung J, Lai CL, Hung I, et al..** "Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin". The Journal of Infectious Diseases (2008): 808–12...
- 38- **Gad RRMales S, El Makhzangy H, Shouman S, et al.** Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. **Liver Int.**2008 Sep; 28(8):1112-9. Epub 2008 Apr 7
- 39- **Ge D, Fellay J, Thompson AJ, et al.** "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature (2009): 399–401..
-
-

-
-
- 40- **Hahn JA.** "Sex, Drugs, and Hepatitis C Virus". *J Infect Dis* (2007): 1556–9..
- 41- **Halfon P, Munteanu M, Poynard T et al.** "FibroTest-ActiTest as a non-invasive marker of liver fibrosis". *Gastroentérologie Clinique* (2008) et *Biologique* **32** (6 Suppl 1): 22–39..
- 42- **Hassan MM, Zaghloul AS, El-Serag HB, et al.** The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. *J Clin Gastroenterol* **2001**;33: 123–6
- 43- **Helal TE, Danial MF, Ahmed HF.** The relationship between hepatitis C virus and schistosomiasis: histopathologic evaluation of liver biopsy specimens. *Hum Pathol* **1998**; 29: 743-749.
- 44- **Hepburn MJ, Hepburn LM, Cantu NS, et al.** Differences in treatment outcome for hepatitis C among ethnic groups. *Am J Med.* Aug 1 **2004**; 117(3):163-8.
- 45- **Hinrichsen H, Benhamou Y, Wedemeyer H, et al.** ("Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients". *Gastroenterology* (**2004**): 1347–55..
- 46- **Houghton M.** "The long and winding road leading to the identification of the hepatitis C virus". *Journal of Hepatology* (**2009**):...
-
-

-
-
- 47- **Houghton, M., Q.-L. Choo, and G. Kuo. *et al*** NANBV
Diagnostics and Vaccines.. European Patent Office
(1989).
- 48- **Hwang LY, Kramer JR, Troisi C, , *et al***.Relationship of
cosmetic procedures and drug use to hepatitis C and
hepatitis B virus infections in a low-risk population.
HEPATOLOGY 2006; 44:341-351.
- 49- **Jacobson IM, Ahmed F, Russo MW, *et al***. Interferon alfa-2b
[correction of alpha-2b]and ribavirin for patients
with chronic hepatitis C and normal ALT. **Am J
Gastroenterol. Sep 2004**; 99(9):1700-5.
- 50- **Jacobson IM, Brown RS Jr, Freilich B, *et al***. Peginterferon
alfa-2b and weight-based or flat-dose ribavirin in
chronic hepatitis C patients: a randomized trial.
HEPATOLOGY 2007;46:971-981.
- 51- **Jaeckel E, Cornberg M, Wedemeyer H, *et al***. "Treatment of
acute hepatitis C with interferon alfa-2b". New
England Journal of Medicine **(2001)**: 1452–1457.
- 52- **Jessner W, Stauber R, Hackl F, *et al***. Early viral kinetics on
treatment with pegylated interferon-alpha-2a in
chronic hepatitis C virus genotype 1 infection. **J
Viral Hepat 2003**; 10:37–42.
-
-

-
-
- 53- **Johnson RJ, Gretch DR, Yamabe H, et al.** "Membranoproliferative glomerulonephritis associated with hepatitis C virus infection". The New England Journal of Medicine **1993**: 465–70.
- 54- **Kamal SM.** "Acute hepatitis C: a systematic review". The American Journal of Gastroenterology **(2008)**: 1283–97; quiz 1298...
- 55- **Kamel, M.A., Ghaffar, Y.A., Wasef, M.A., et al** High HCV prevalence in Egyptian Blood donors. Lancet. 1992.
- 56- **Karmochkine M, Carrat F, Dos Santos O, et al.** "A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection". Journal of Viral Hepatitis(2006): 775–82..
- 57- **King CL, Medhat A, Malhotra I, et al.** Cytokine control of parasite-specific anergy in human urinary schistosomiasis. IL-10 modulates lymphocyte reactivity. **J Immunol 1996**; 156: 4715–4721.
- 58- **Kuo G, Choo QL, Alter HJ, et al.** "An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis". Science **(1989)**: 362–4..
- 59- **Lagging M, Langeland N, Pedersen C, et al.** "Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection". Hepatology **(2008)**: 695.
-
-

-
-
- 60- **Lagging M, Langeland N, Pedersen C, et al.** "Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection". *Hepatology*(2008): 1837–45..
- 61- **Lagging M, Romero AI, Westin J, et al.** "IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection". *Hepatology* (2006): 1617–25..
- 62- **Lagging M, Wejstål R, Uhnöo I, et al.** "Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations". *Scandinavian Journal of Infectious Diseases* 2009: 389–402..
- 63- **Lamarre D, Anderson PC, Bailey M, et al.** (November 2003). "An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus". *Nature* 426 (6963): 186–9. doi: 10.1038/nature02099. PMID 14578911.
- 64- **Leutscher PD, Lagging M, Buhl MR, et al.** "Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C". *Hepatology* 2010
- 65- **Lock G, Dirscherl M, Obermeier F, et al.** "Hepatitis C - contamination of toothbrushes: myth or reality?". *J. Viral Hepat.* (2006): 571–3..
-
-

-
-
- 66- **Lundy SK, Lerman SP & Boros DL.** Soluble egg antigenstimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL (+) T and B cells during murine *Schistosoma mansoni* infection. **Infect Immun** **2001**; 69: 271–280.
- 67- **Malaquias LC, Falcao PL, Silveira AM, et al.** Cytokine regulation of human immune response to *Schistosoma mansoni*: analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. **Scand J Immunol** **1997**; 46: 393–398.
- 68- **Manns MP, Foster GR, Rockstroh JK, et al.** "The way forward in HCV treatment—finding the right path". *Nat Rev Drug Discov* (**2007**): 991–1000..
- 69- **Manns MP, McHutchison JG, Gordon SC et al.** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. **Lancet. Sep 22 2001**; 358(9286):958-65.
- 70- **Mast EE** "**Mother-to-infant hepatitis C virus transmission and breastfeeding**". *Advances in Experimental Medicine and Biology* **2004**: 211–6..
- 71- **Maynard M, Pradat P, Bailly F, et al..** "Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI)". *Journal of Hepatology* **2006**: 484–90..
-
-

-
-
- 72- **McCaffrey AP, Meuse L, Karimi M, et al.** "A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice". *Hepatology* **2003**: 503–8..
- 73- **McGovern BH, Wurcel A, Kim AY, et al..** "Acute hepatitis C virus infection in incarcerated injection drug users". *Clinical Infectious Diseases* **(2006)**: 1663–70.
- 74- **McHutchison JG, Everson GT, Gordon SC, et al.** Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med.* **Apr 30 2009**; 360(18):1827-38.
- 75- **McHutchison JG, Gordon SC, Schiff ER, et al.** Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med.* **Nov 19 1998**; 339(21):1485-92.
- 76- **McHutchison JG, Poynard T, Pianko S, et al.** The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. *Gastroenterology* **2000**; 119:1317–1323.
- 77- **Missiha S, Heathcote J, Arenovich T, Khan K.** Impact of asianrace on response to combination therapy with peginterferon alfa- 2a and ribavirin in chronic hepatitis C. *Am J Gastroenterol* **2007**;102:2181–2188.
-
-

-
-
- 78- **Monto A, Alonzo J, Watson JJ, et al.** Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. **Hepatology** 2002; 36:729–736.
- 79- **MW Fried, SJ Hadziyannis, M Shiffman, et al.** Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. 43rd annual meeting of the European Association for the Study of the Liver (**EASL 2008**). Milan, Italy. April 23-27, 2008.
- 80- **NCCAM.** Hepatitis C and Complementary and Alternative Medicine: 2003 Update. May 2004. Retrieved 25 February 2007.
- 81- **Ngo Y, Munteanu M, Messous D, et al..** "A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C". *Clinical Chemistry* (2006): 1887–96.
- 82- **Ortiz V, Berenguer M, Rayon JM, et al.** Contribution of obesity to hepatitis C-related fibrosis progression. **Am J Gastroenterol** 2002;97:2408–2414.
- 83- **Pascual M, Perrin L, Giostra E, Schifferli JA et al.** "Hepatitis C virus in patients with cryoglobulinemia type II". *The Journal of Infectious Diseases* 1990:
-
-

-
- 84- **Pawelec G, Barnett Y, Forsey R, et al.** *T cells and aging, January 2002 update. Front Biosci 2002;7:d1056-183.*
- 85- **Paul Elias.** "'Hepatitis Drug-Maker Complaints Reviewed", The Associated Press, 27 February 2004
- 86- **Pellicano R, Puglisi G, Ciancio A, et al.** Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? *J. Med. Virol.* **2008**; 80:628-631,
- 87- **Poo, Jorge L.;** Francisco Sánchez Ávila; David Kershenobich; Xochitl García Samper; Rocío Torres-Ibarra; Julieta Góngora; Carlos Cano; Miguel Parada;1 Misael Uribe *et al.* "Efficacy of triple therapy with thymalfasin, peginterferon α -2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders" (PDF). *Annals of Hepatology*(2008).
- 88- **Poynard T, Marcellin P, Lee SS, et al.** Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet.* **Oct 31 1998**; 352(9138):1426-32.
-

-
-
- 89- **Poynard T, McHutchison J, Goodman Z, *et al.*** Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. **HEPATOLOGY** 2000;31:211-218
- 90- **Poynard T, McHutchison J, Manns M *et al.*** Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. **Gastroenterology**. May 2002; 122(5):1303-13.
- 91- **Poynard T, Ratziu V, McHutchison J, *et al.*** Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. **HEPATOLOGY** 2003;38:75-85.
- 92- **Poynard T, Ratziu V, Charlotte F, *et al.*** Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. **J Hepatol** 2001; 34:730-739.
- 93- **Pradat P, Tillmann HL, Sauleda S, *et al.*** Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. **J Viral Hepat** 2007; 14:556-563.
- 94- **Reddy KR, Hoofnagle JH, Tong MJ, *et al.*** Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. **Hepatology** 1999; 30:787–79
-
-

-
-
- 95- **Romero AI, Lagging M, Westin J, et al.** "Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection". *The Journal of Infectious Diseases* **2006**: 895–903..
- 96- **Ruiz JD, Molitor F, Plagenhoef JA et al.** "Trends in hepatitis C and HIV infection among inmates entering prisons in California, 1994 versus 1999". 2002: 2236–8...
- 97- **Ryan KJ, Ray CG (editors), .** *Sherris Medical Microbiology* (4th ed.). McGraw Hill. 2004. 551–2..
- 98- **Salmeron J, Casado J, Rueda PM, et al.** Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. *J Clin Virol* **2008**; 41:264–269.
- 99- **Salyer, David.** "Pamela Anderson: The Newest Hepatitis C Poster Girl". *The Body*. 2010-08-27.
- 100- **Scott JD, McMahon BJ, Bruden D, et al.** "High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives". *Clinical Infectious Diseases* (**2006**): 945–52.
-
-

-
-
- 101- **Shiffman ML, Diago M, Tran A, Pockros P, *et al.*** "Chronic hepatitis C in patients with persistently normal alanine transaminase levels". *Clinical Gastroenterology and Hepatology* **2006**: 645–52.
- 102- **Shiffman ML, Suter F, Bacon BR, *et al.*** "Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3". *The New England Journal of Medicine* **2007**: 124–34..
- 103- **Shepard CW, Finelli L, Alter MJ.** Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005;5:558-67
- 104- **Strickland GT, Elhefni H, Salman T, *et al.*** Role of hepatitis C infection in chronic liver disease in Egypt. *Am J Trop Med Hyg* **2002**; 67:436–42.
- 105- **Strickland GT.** Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. *Hepatology* **2006**;43:915–22
- 106- **Thomas DL, Thio CL, Martin MP, *et al.*** (October 2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". *Nature* **2009**: 798–801.
- 107- **Tohme RA, Holmberg SD.** "Is sexual contact a major mode of hepatitis C virus transmission?". *Hepatology* **2010**: n/a..
-
-

-
- 108- **Van der Kleij D, Latz E, Brouwers JF, *et al.*** A novel hostparasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. **J Biol Chem** **2002**; 277: 48122–48129.
- 109- **Van Thiel DH, Faruki H, Friedlander L, *et al.*** Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. *Hepatogastroenterology*. **Nov-Dec 1995**; 42(6): 907-12.
- 110- **Van Thiel DH, Friedlander L, Fagiuoli S, *et al.*** Response to interferon alpha therapy is influenced by the iron content of the liver. **J Hepatol** **1994**; 20:410–415.
- 111- **Vandelli C, Renzo F, Romanò L, *et al.*** "Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study". *The American Journal of Gastroenterology* **2004**: 855–9..
- 112- **Vescio MF, Longo B, Babudieri S, *et al.*** "Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis". *Journal of Epidemiology and Community Health* **2008**: 305–13.
- 113- **Villano SA, Vlahov D, Nelson KE, *et al.*** "Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection". *Hepatology* **1999**: 908–14.
-

-
- 114- **Watanabe H, Saito T, Shinzawa H, et al.** "Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study". *Journal of Medical Virology* 2003; 56–61.
- 115- **Zeuzem S, Diago M, Gane E, et al.** Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. *Gastroenterology* 2004; 127:1724-1732.
- 116- **Zeuzem S, Feinman SV, Rasenack J, et al.** Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med.* Dec 7 2000 ;343(23):1666-72.
- 117- **Zeuzem S, Fried MW, Reddy KR, et al.** Improving the clinical relevance of pretreatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (COPEGUS (R)). *Hepatology* 2006; 44 (Suppl. 1):267A–268A.
- 118- **Zeuzem S, Herrmann E, Lee JH, et al.** Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. *Gastroenterology* 2001; 120:1438–1447.
-

-
- 119- . **Zanni F, Vescovini R, Biasini C, et al.**(Marked increase with age of type I cytokines within memory and effector/cytotoxic CD8⁺ T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. *Exp Gerontol* 2003;38:981-7.
- 120- **Zeuzem S, Hultcrantz R, Bourliere M, et al.** Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. *J Hepatol* 2004; 40:993–999.
- 121- **Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK.** Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. *Hepatology* 1996; 23:366–371.
- 122- **Zeuzem S, Welsch C, Herrmann E.** Pharmacokinetics of peginterferons. *Semin Liver Dis* 2003; 23(Suppl 1):23-28.
- 123- **Zeuzem S, Buti M, Ferenci P, et al.**Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol* 2006; 44:97–103.
-

-
- 124- **Zhang H, Hanecak R, Brown-Driver V, et al.** "Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant". *Antimicrobial Agents and Chemotherapy* **1999**: 347–53.
- 125- **Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB et al.** "Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach". *Digestive and Liver Disease* **2007**:
-